Who is sponsoring NCT00327743?

NCT00327743 is sponsored by Sanofi.

What condition does NCT00327743 study?

NCT00327743 studies Breast Cancer, Cancer.

What drugs are being tested in NCT00327743?

Interventions: larotaxel, capecitabine.

What is the status of NCT00327743?

NCT00327743 is currently COMPLETED.

Last reviewed 2016-04-18 · How we verify

A Dose-escalating, Multicenter, Single Arm, Open-Label Study of XRP9881 in Combination With Capecitabine (Xeloda), in Metastatic Breast Cancer Patients With Disease Progressing After Anthracycline and Taxane Therapy

NCT00327743 Phase 1/Phase 2 COMPLETED

The goal of this phase I-II clinical research study is to find the highest safe dose of XRP9881 and capecitabine that can be given in combination in the treatment of metastatic breast cancer in patients who have been previously treated by taxanes and anthracyclines. The safety and effectiveness of this combination will also be studied. Patients participating in the study will be asked to give additional blood samples to look at the level of study drugs in the blood.

Details

Lead sponsor	Sanofi
Phase	Phase 1/Phase 2
Status	COMPLETED
Enrolment	34
Start date	2006-08
Completion	2009-03

Conditions

Breast Cancer
Cancer

Interventions

larotaxel
capecitabine

Primary outcomes

Safety, tolerability, and maximum tolerated dose (MTD) of XRP9881 when given in combination with capecitabine — study period

Countries

United States, France